A Phase 3 interventional study of AMG 162 and Placebo in Postmenopausal Osteoporosis, sponsored by Amgen. Completed. Open to female participants aged Up to 90 Years. Per ClinicalTrials.gov, last updated 2010-12-31.
Sponsored by Amgen · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 14th largest by enrollment, is one of 2 that started in 2004, is one of 17 in phase 3, and was the 2nd registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:
Lambda Therapeutic Research Ltd. · Sites in India
Ages 55–90 · Women only
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: Up to 90 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 332 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 278 across the 31 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 31 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
24 studies in Osteoporosis, Postmenopausal by Amgen: none open now, none under way, none of them phase 3. Of 24 finished, 23 (96%) have results posted.
Among the 24 studies in Osteoporosis, Postmenopausal by Amgen, this one is the 12th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2004, is one of 14 in phase 3, and was the 2nd registered.
Amgen’s Osteoporosis, Postmenopausal studies by the year they started, since 2004.
1 of the studies testing denosumab in Osteoporosis, Postmenopausal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05010590Massachusetts General HospitalAnabolic Therapy in Postmenopausal Osteoporosis | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 24 in Osteoporosis, Postmenopausal:
This tab as a report to print or save as PDF → With an account.
This study will determine whether treatment with AMG 162 can prevent lumbar spine bone loss in both early and late postmenopausal women with osteopenia, and to further test the safety and tolerability of AMG 162 in this population.
Eligibility Criteria
- women with Osteopenia (lumbar spine bone mineral density T-score between 1.0 and -2.5)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
60 mg/mL denosumab given day 1, month 6, month 12 and month 18
Drug: AMG 162
Placebo given day 1, month 6, month 12 and month 18
Drug: Placebo
60 mg/mL denosumab given day 1, month 6, month 12 and month 18
Placebo given at day 1, month 6, month 12 and month 18
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 24 Months
Total Hip Bone Mineral Density Percent Change From Baseline at Month 24
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 24 Months
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 24 Months
Trochanter Bone Mineral Density Percent Change From Baseline at Month 24
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 24 months
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 24 months
Total Body (Without Head) Bone Mineral Density Percent Change From Baseline at Month 24
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
Time frame: 24 months
Distal Radius Trabecular Volumetric Bone Mineral Density Percent Change From Baseline at Month 24
Volumetric Bone Mineral Density Assessed by Quantitative Computerized Tomography (QCT).
Time frame: 24 months
Distal Radius Cortical Volumetric Bone Mineral Density Percent Change From Baseline at Month 24
Volumetric Bone Mineral Density Assessed by Quantitative Computerized Tomography (QCT).
Time frame: 24 months
Distal Radius Total Volumetric Bone Mineral Density Percent Change From Baseline at Month 24
Volumetric Bone Mineral Density Assessed by Quantitative Computerized Tomography (QCT).
Time frame: 24 months
| Milestone | Denosumab 60 mg Q6M | Placebo |
|---|---|---|
| Started | 166 | 166 |
| Completed | 142 | 144 |
| Not completed | 24 | 22 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Withdrawal by subject | 10 | 15 |
| Withdrew: Ineligibility determined | 2 | 0 |
| Withdrew: Lost to follow-up | 7 | 5 |
| Withdrew: Noncompliance | 2 | 0 |
| Withdrew: Other | 2 | 0 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Denosumab 60 mg Q6M | Placebo |
|---|---|---|
| Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24 | 6.5 (5.8 to 7.2) | -.6 (-1.2 to .1) |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Denosumab 60 mg Q6M | Placebo |
|---|---|---|
| Total Hip Bone Mineral Density Percent Change From Baseline at Month 24 | 3.4 (3.0 to 3.7) | -1.1 (-1.5 to -.8) |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Denosumab 60 mg Q6M | Placebo |
|---|---|---|
| Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24 | 2.8 (2.3 to 3.3) | -.9 (-1.4 to -.3) |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Denosumab 60 mg Q6M | Placebo |
|---|---|---|
| Trochanter Bone Mineral Density Percent Change From Baseline at Month 24 | 5.2 (4.7 to 5.6) | -.8 (-1.3 to -.3) |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Denosumab 60 mg Q6M | Placebo |
|---|---|---|
| Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24 | 1.4 (.9 to 1.9) | -2.1 (-2.6 to -1.6) |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
| Percent Change from Baseline | Denosumab 60 mg Q6M | Placebo |
|---|---|---|
| Total Body (Without Head) Bone Mineral Density Percent Change From Baseline at Month 24 | 2.4 (1.9 to 2.9) | -1.4 (-1.9 to -.8) |
Volumetric Bone Mineral Density Assessed by Quantitative Computerized Tomography (QCT).
| Percent Change from Baseline | Denosumab 60 mg Q6M | Placebo |
|---|---|---|
| Distal Radius Trabecular Volumetric Bone Mineral Density Percent Change From Baseline at Month 24 | 8.7 (3 to 14.4) | -.7 (-6.6 to 5.3) |
Volumetric Bone Mineral Density Assessed by Quantitative Computerized Tomography (QCT).
| Percent Change from Baseline | Denosumab 60 mg Q6M | Placebo |
|---|---|---|
| Distal Radius Cortical Volumetric Bone Mineral Density Percent Change From Baseline at Month 24 | .3 (-.1 to .8) | -1.4 (-1.8 to -.9) |
Volumetric Bone Mineral Density Assessed by Quantitative Computerized Tomography (QCT).
| Percent Change from Baseline | Denosumab 60 mg Q6M | Placebo |
|---|---|---|
| Distal Radius Total Volumetric Bone Mineral Density Percent Change From Baseline at Month 24 | .8 (0 to 1.6) | -1.9 (-2.6 to -1.1) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 9/165 (5.5%) | 157/165 (95.2%) |
| Denosumab 60 mg Q6M | — | 18/164 (11%) | 156/164 (95.1%) |
| Event | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| PneumoniaInfections and infestations | 0/165 | 3/164 |
| DiverticulitisInfections and infestations | 0/165 | 2/164 |
| SepsisInfections and infestations | 0/165 | 2/164 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/165 | 2/164 |
| Colitis ischaemicGastrointestinal disorders | 0/165 | 1/164 |
| Colonic polypGastrointestinal disorders | 0/165 | 1/164 |
| AppendicitisInfections and infestations | 0/165 | 1/164 |
| CellulitisInfections and infestations | 0/165 | 1/164 |
| PyelonephritisInfections and infestations | 0/165 | 1/164 |
| Urinary tract infectionInfections and infestations | 0/165 | 1/164 |
| Event | Placebo | Denosumab 60 mg Q6M |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 42/165 | 41/164 |
| NasopharyngitisInfections and infestations | 31/165 | 36/164 |
| Back painMusculoskeletal and connective tissue disorders | 33/165 | 33/164 |
| HeadacheNervous system disorders | 19/165 | 26/164 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 20/165 | 24/164 |
| Upper respiratory tract infectionInfections and infestations | 22/165 | 19/164 |
| ConstipationGastrointestinal disorders | 8/165 | 18/164 |
| Urinary tract infectionInfections and infestations | 17/165 | 18/164 |
| InfluenzaInfections and infestations | 18/165 | 15/164 |
| Shoulder painMusculoskeletal and connective tissue disorders | 10/165 | 17/164 |
| Age Continuous(Years) | Denosumab 60 mg Q6M | Placebo | Total |
|---|---|---|---|
| Mean | 59.8 ± 7.4 | 58.9 ± 7.5 | 59.4 ± 7.5 |
| Sex: Female, Male(Participants) | Denosumab 60 mg Q6M | Placebo | Total |
|---|---|---|---|
| Female | 166 | 166 | 332 |
| Male | 0 | 0 | 0 |
No study locations are listed for this record.
The record gives a start of Aug 2004, a primary completion of Feb 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 11 months after primary completion. A results delay was requested in Nov 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab
Osteoporosis, Postmenopausal →